Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, points to a new challenge to the MedTech sector of deliver devices to tackle substance addiction.
The UK government has opened a major new funding opportunity for innovators developing technologies to address drug and alcohol addiction – an area where unmet clinical need, rising societal costs and rapid advances in digital health are converging. With 20 million GBP now available through Innovate UK, the initiative signals a clear call to action for medical device developers, digital therapeutics companies and life sciences entrepreneurs.
Substance misuse remains one of the most persistent public health challenges in the UK. Around 15,000 people die each year from drug- and alcohol‑related causes, and hundreds of thousands more experience long‑term harm. The economic impact is equally stark, with addiction estimated to cost England 47 billion GBP annually. Against this backdrop, the government’s Addiction Healthcare Goals (AHG) programme aims to accelerate the development and deployment of technologies that can reduce harm, improve treatment outcomes and strengthen long‑term recovery.
For medical device innovators, the AHG Catalysing Innovation Awards represent a rare combination of substantial funding, regulatory support and a clear route to real‑world adoption. Grants of up to 10 million GBP will be available for late‑stage, high‑impact technologies that can demonstrate effectiveness, market readiness and progress toward regulatory approval. A second funding stream will provide up to 1.5 million GBP for earlier‑stage concepts, helping companies generate initial evidence, refine business models and prepare for scale.
The scope is intentionally broad. Eligible innovations include wearables capable of monitoring physiological markers of relapse risk, AI‑enabled decision‑support tools for clinicians, virtual‑reality therapies for behavioural change, treatment‑adherence technologies, and novel medical devices or medicines targeting addiction pathways. This breadth reflects a growing recognition that addiction is a complex, multifactorial condition requiring equally multifaceted technological solutions.
Crucially, successful applicants will gain access to dedicated sessions with the MHRA and NICE – an invaluable opportunity for device developers navigating evidence requirements, clinical evaluation pathways and UKCA/CE marking strategies. For companies seeking to accelerate time‑to‑market, this regulatory engagement may prove as valuable as the funding itself.
Government leaders have emphasised both the human and economic stakes. Health Minister Dr Zubir Ahmed highlighted the potential for new technologies to “ease the suffering” of those affected and complement existing investments in treatment and recovery services. Science Minister Lord Vallance underscored the importance of supporting both breakthrough ideas and near‑deployment solutions, creating a pipeline from research to real‑world impact. Leaders from the Office for Life Sciences and Innovate UK echoed the urgency of bringing effective innovations into clinical settings quickly.
For medical device innovators, the message is clear: the UK is positioning itself as a global hub for addiction‑focused health technologies, backed by funding, regulatory alignment and a strong national mandate. With applications open until 6 May 2026, companies developing tools that can prevent relapse, reduce overdose risk or enhance treatment engagement have a significant opportunity to secure support and accelerate deployment.
More information about the funding available and where to apply is on Innovate UK’s website: supporting innovation in drug and alcohol addiction healthcare challenges.
The author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
